Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use

George L. Bakris, John M. Burkart, Eric D. Weinhandl, Peter A. McCullough, Michael Kraus

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Hypertension is a cardinal feature of end-stage renal disease (ESRD). Hypertensive nephropathy is the primary cause of ESRD for nearly 30% of patients, and the prevalence of hypertension is >85% in new patients with ESRD. In contemporary hemodialysis (HD) patients, mean predialysis systolic blood pressure (SBP) is nearly 150 mm Hg, and about 70%, 50%, and 40% use β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors, respectively. Predialysis SBP generally exhibits a U-shaped association with mortality risk. Interdialytic ambulatory SBP is more strongly associated with risk. Hypertension is multifactorial; key causes include persistent hypervolemia and elevated peripheral resistance. With 3 HD sessions per week, blood pressure (BP) climbs during the interdialytic interval, in step with interdialytic weight gain, particularly among elderly patients and those with higher dry weight. Elevated peripheral resistance can be attributed to inappropriate activation of the sympathetic nervous system due to higher plasma norepinephrine concentrations. Multiple randomized clinical trials show that intensive HD reduces BP and the need for oral medications indicated for hypertension. In the first 2 months of the Frequent Hemodialysis Network trial, the short daily schedule reduced predialysis SBP by 7.7 mm Hg, whereas the nocturnal schedule reduced predialysis SBP by 7.3 mm Hg, both relative to 3 sessions per week. Improvements were sustained after 12 months. Both schedules reduced antihypertensive medication use relative to 3 sessions per week. In FREEDOM (Following Rehabilitation, Economics, and Everyday-Dialysis Outcome Measurements), a prospective cohort study of short daily HD, the mean number of prescribed antihypertensive agents decreased from 1.7 to 1.0 in 1 year, whereas the percentage of patients not prescribed antihypertensive agents increased from 21% to 47%. Nocturnal HD appears to markedly reduce total peripheral resistance and plasma norepinephrine and restore endothelium-dependent vasodilation. In conclusion, intensive HD reduces BP and the need for antihypertensive medications.

Original languageEnglish (US)
Pages (from-to)S15-S23
JournalAmerican Journal of Kidney Diseases
Volume68
Issue number5
DOIs
StatePublished - Nov 1 2016

Fingerprint

Antihypertensive Agents
Renal Dialysis
Blood Pressure
Vascular Resistance
Chronic Kidney Failure
Hypertension
Appointments and Schedules
Norepinephrine
Sympathetic Nervous System
Calcium Channel Blockers
Renin-Angiotensin System
Vasodilation
Weight Gain
Endothelium
Dialysis
Cohort Studies
Rehabilitation
Randomized Controlled Trials
Economics
Prospective Studies

Keywords

  • Antihypertensive medication
  • blood pressure
  • cardiovascular disease
  • chronic kidney disease
  • daily dialysis
  • end-stage renal disease (ESRD)
  • fluid overload
  • Frequent Hemodialysis Network
  • home dialysis
  • hypertension
  • intensive hemodialysis
  • nocturnal hemodialysis
  • review
  • short daily hemodialysis
  • ultrafiltration

ASJC Scopus subject areas

  • Nephrology

Cite this

Bakris, G. L., Burkart, J. M., Weinhandl, E. D., McCullough, P. A., & Kraus, M. (2016). Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. American Journal of Kidney Diseases, 68(5), S15-S23. https://doi.org/10.1053/j.ajkd.2016.05.026

Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. / Bakris, George L.; Burkart, John M.; Weinhandl, Eric D.; McCullough, Peter A.; Kraus, Michael.

In: American Journal of Kidney Diseases, Vol. 68, No. 5, 01.11.2016, p. S15-S23.

Research output: Contribution to journalArticle

Bakris, GL, Burkart, JM, Weinhandl, ED, McCullough, PA & Kraus, M 2016, 'Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use', American Journal of Kidney Diseases, vol. 68, no. 5, pp. S15-S23. https://doi.org/10.1053/j.ajkd.2016.05.026
Bakris, George L. ; Burkart, John M. ; Weinhandl, Eric D. ; McCullough, Peter A. ; Kraus, Michael. / Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. In: American Journal of Kidney Diseases. 2016 ; Vol. 68, No. 5. pp. S15-S23.
@article{fd80ca32f5644ea7a67975781ad92ed0,
title = "Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use",
abstract = "Hypertension is a cardinal feature of end-stage renal disease (ESRD). Hypertensive nephropathy is the primary cause of ESRD for nearly 30{\%} of patients, and the prevalence of hypertension is >85{\%} in new patients with ESRD. In contemporary hemodialysis (HD) patients, mean predialysis systolic blood pressure (SBP) is nearly 150 mm Hg, and about 70{\%}, 50{\%}, and 40{\%} use β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors, respectively. Predialysis SBP generally exhibits a U-shaped association with mortality risk. Interdialytic ambulatory SBP is more strongly associated with risk. Hypertension is multifactorial; key causes include persistent hypervolemia and elevated peripheral resistance. With 3 HD sessions per week, blood pressure (BP) climbs during the interdialytic interval, in step with interdialytic weight gain, particularly among elderly patients and those with higher dry weight. Elevated peripheral resistance can be attributed to inappropriate activation of the sympathetic nervous system due to higher plasma norepinephrine concentrations. Multiple randomized clinical trials show that intensive HD reduces BP and the need for oral medications indicated for hypertension. In the first 2 months of the Frequent Hemodialysis Network trial, the short daily schedule reduced predialysis SBP by 7.7 mm Hg, whereas the nocturnal schedule reduced predialysis SBP by 7.3 mm Hg, both relative to 3 sessions per week. Improvements were sustained after 12 months. Both schedules reduced antihypertensive medication use relative to 3 sessions per week. In FREEDOM (Following Rehabilitation, Economics, and Everyday-Dialysis Outcome Measurements), a prospective cohort study of short daily HD, the mean number of prescribed antihypertensive agents decreased from 1.7 to 1.0 in 1 year, whereas the percentage of patients not prescribed antihypertensive agents increased from 21{\%} to 47{\%}. Nocturnal HD appears to markedly reduce total peripheral resistance and plasma norepinephrine and restore endothelium-dependent vasodilation. In conclusion, intensive HD reduces BP and the need for antihypertensive medications.",
keywords = "Antihypertensive medication, blood pressure, cardiovascular disease, chronic kidney disease, daily dialysis, end-stage renal disease (ESRD), fluid overload, Frequent Hemodialysis Network, home dialysis, hypertension, intensive hemodialysis, nocturnal hemodialysis, review, short daily hemodialysis, ultrafiltration",
author = "Bakris, {George L.} and Burkart, {John M.} and Weinhandl, {Eric D.} and McCullough, {Peter A.} and Michael Kraus",
year = "2016",
month = "11",
day = "1",
doi = "10.1053/j.ajkd.2016.05.026",
language = "English (US)",
volume = "68",
pages = "S15--S23",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use

AU - Bakris, George L.

AU - Burkart, John M.

AU - Weinhandl, Eric D.

AU - McCullough, Peter A.

AU - Kraus, Michael

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Hypertension is a cardinal feature of end-stage renal disease (ESRD). Hypertensive nephropathy is the primary cause of ESRD for nearly 30% of patients, and the prevalence of hypertension is >85% in new patients with ESRD. In contemporary hemodialysis (HD) patients, mean predialysis systolic blood pressure (SBP) is nearly 150 mm Hg, and about 70%, 50%, and 40% use β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors, respectively. Predialysis SBP generally exhibits a U-shaped association with mortality risk. Interdialytic ambulatory SBP is more strongly associated with risk. Hypertension is multifactorial; key causes include persistent hypervolemia and elevated peripheral resistance. With 3 HD sessions per week, blood pressure (BP) climbs during the interdialytic interval, in step with interdialytic weight gain, particularly among elderly patients and those with higher dry weight. Elevated peripheral resistance can be attributed to inappropriate activation of the sympathetic nervous system due to higher plasma norepinephrine concentrations. Multiple randomized clinical trials show that intensive HD reduces BP and the need for oral medications indicated for hypertension. In the first 2 months of the Frequent Hemodialysis Network trial, the short daily schedule reduced predialysis SBP by 7.7 mm Hg, whereas the nocturnal schedule reduced predialysis SBP by 7.3 mm Hg, both relative to 3 sessions per week. Improvements were sustained after 12 months. Both schedules reduced antihypertensive medication use relative to 3 sessions per week. In FREEDOM (Following Rehabilitation, Economics, and Everyday-Dialysis Outcome Measurements), a prospective cohort study of short daily HD, the mean number of prescribed antihypertensive agents decreased from 1.7 to 1.0 in 1 year, whereas the percentage of patients not prescribed antihypertensive agents increased from 21% to 47%. Nocturnal HD appears to markedly reduce total peripheral resistance and plasma norepinephrine and restore endothelium-dependent vasodilation. In conclusion, intensive HD reduces BP and the need for antihypertensive medications.

AB - Hypertension is a cardinal feature of end-stage renal disease (ESRD). Hypertensive nephropathy is the primary cause of ESRD for nearly 30% of patients, and the prevalence of hypertension is >85% in new patients with ESRD. In contemporary hemodialysis (HD) patients, mean predialysis systolic blood pressure (SBP) is nearly 150 mm Hg, and about 70%, 50%, and 40% use β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors, respectively. Predialysis SBP generally exhibits a U-shaped association with mortality risk. Interdialytic ambulatory SBP is more strongly associated with risk. Hypertension is multifactorial; key causes include persistent hypervolemia and elevated peripheral resistance. With 3 HD sessions per week, blood pressure (BP) climbs during the interdialytic interval, in step with interdialytic weight gain, particularly among elderly patients and those with higher dry weight. Elevated peripheral resistance can be attributed to inappropriate activation of the sympathetic nervous system due to higher plasma norepinephrine concentrations. Multiple randomized clinical trials show that intensive HD reduces BP and the need for oral medications indicated for hypertension. In the first 2 months of the Frequent Hemodialysis Network trial, the short daily schedule reduced predialysis SBP by 7.7 mm Hg, whereas the nocturnal schedule reduced predialysis SBP by 7.3 mm Hg, both relative to 3 sessions per week. Improvements were sustained after 12 months. Both schedules reduced antihypertensive medication use relative to 3 sessions per week. In FREEDOM (Following Rehabilitation, Economics, and Everyday-Dialysis Outcome Measurements), a prospective cohort study of short daily HD, the mean number of prescribed antihypertensive agents decreased from 1.7 to 1.0 in 1 year, whereas the percentage of patients not prescribed antihypertensive agents increased from 21% to 47%. Nocturnal HD appears to markedly reduce total peripheral resistance and plasma norepinephrine and restore endothelium-dependent vasodilation. In conclusion, intensive HD reduces BP and the need for antihypertensive medications.

KW - Antihypertensive medication

KW - blood pressure

KW - cardiovascular disease

KW - chronic kidney disease

KW - daily dialysis

KW - end-stage renal disease (ESRD)

KW - fluid overload

KW - Frequent Hemodialysis Network

KW - home dialysis

KW - hypertension

KW - intensive hemodialysis

KW - nocturnal hemodialysis

KW - review

KW - short daily hemodialysis

KW - ultrafiltration

UR - http://www.scopus.com/inward/record.url?scp=84994802503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994802503&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2016.05.026

DO - 10.1053/j.ajkd.2016.05.026

M3 - Article

C2 - 27772639

AN - SCOPUS:84994802503

VL - 68

SP - S15-S23

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -